Macquarie Group Ltd. acquired a new position in shares of Insulet Co. (NASDAQ:PODD) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 21,628 shares of the medical instruments supplier’s stock, valued at approximately $1,191,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Insulet by 11.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after buying an additional 235 shares during the period. SG Americas Securities LLC purchased a new position in Insulet during the second quarter worth $180,000. Wrapmanager Inc. purchased a new position in Insulet during the second quarter worth $217,000. RNC Capital Management LLC purchased a new position in Insulet during the second quarter worth $225,000. Finally, Strs Ohio boosted its stake in Insulet by 35.0% during the second quarter. Strs Ohio now owns 5,400 shares of the medical instruments supplier’s stock worth $277,000 after buying an additional 1,400 shares during the period.

Shares of Insulet Co. (PODD) opened at $69.76 on Friday. Insulet Co. has a 52-week low of $36.68 and a 52-week high of $72.99. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. During the same period last year, the company earned ($0.05) earnings per share. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. sell-side analysts predict that Insulet Co. will post -0.42 earnings per share for the current fiscal year.

PODD has been the subject of several recent analyst reports. Barclays lifted their price objective on shares of Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Monday, November 20th. Morgan Stanley lifted their price objective on shares of Insulet from $55.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Robert W. Baird set a $65.00 price objective on shares of Insulet and gave the stock a “buy” rating in a research note on Friday, October 13th. Finally, Wedbush reaffirmed a “buy” rating and set a $65.00 price objective (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $61.07.

In other news, Director James C. Mullen acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “21,628 Shares in Insulet Co. (PODD) Purchased by Macquarie Group Ltd.” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/09/21628-shares-in-insulet-co-podd-purchased-by-macquarie-group-ltd.html.

Insulet Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Stock Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related stocks with our FREE daily email newsletter.